biorepository News
-
Frost & Sullivan Recognizes Thermo Fisher Scientific for its Superiority in the Global Biobanking Products, Services and Solutions Market
Based on its recent analysis of the integrated biobanking solutions market, Frost & Sullivan recognizes Thermo Fisher Scientific, the world leader in serving science, with the 2011 Global Frost & Sullivan Award for Company of the Year. Thermo Fisher is the world's largest provider of biobanking products, services and solutions, enabling its customers to make the world healthier, cleaner ...
-
First recipients of research grants to support genomic studies in Africa announced
African scientists will conduct genomic research on kidney disease, diabetes, heart disease, obesity, tuberculosis and African sleeping sickness through inaugural grants of the Human Heredity and Health in Africa Consortium (H3Africa). The grants were announced by the two funding organizations, the U.S. National Institutes of Health and the Wellcome Trust, a global charity based in London. The ...
-
Recognizing 10 years of philanthropic support for prostate cancer research
Two powerhouse researchers in prostate cancer will change the way we treat the disease, thanks to funding from legendary volunteer fundraisers, the Bird Dogs and the Alberta Cancer Foundation. Working with the Alberta Cancer Foundation and the University of Alberta, the Bird Dogs have enabled a new one-term, five-year chair position to further prostate cancer research — the Bird Dogs ...
-
A2LA Accredits Cornell Veterinary Biobank to New ISO 20387 International Standard
A2LA is proud to announce the issuance of its first accreditation, and the first such accreditation in the world, to the newly published standard ISO 20387:2018 – Biobanking – General requirements for biobanking. ISO 20387 contains requirements designed to demonstrate the competence of a biobank’s operation and ability to provide biological material and associated data for ...
-
Spatial Biology CRO Flagship Biosciences Acquires Pharma Services Business from Interpace Biosciences
Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the acquisition of Interpace Pharma Solutions® (“IPS”), a division of Interpace Biosciences and provider of cytogenetic, molecular pathology, and genomic profiling solutions. This acquisition follows a growth equity investment in Flagship from Ampersand Capital Partners, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you